economictimes.indiatimes.com ·
anthropic in talks to raise 30 billion at 900 billion valuation
Topic context
This topic has been covered 344343 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedIsomorphic Labs, an AI drug discovery company, is raising $2B+ to expand its AI-driven drug design platform. This signals strong investor appetite for AI in pharma, potentially accelerating drug R&D and reducing costs for partner pharma companies. The funding round is not yet closed; no specific revenue or margin impact quantified. The mechanism is capex_cycle for AI infrastructure and pharma R&D efficiency.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Isomorphic Labs in advanced talks to raise over $2 billion led by Thrive Capital.
- Alphabet Inc. is also participating in the investment.
- Isomorphic Labs has partnerships with Johnson & Johnson, Eli Lilly & Co., and Novartis.
- Funding aims to enhance drug design engine and support global expansion.
- Isomorphic Labs spun out of Google DeepMind in 2021.
